Immutep Highlights Improvement in Interim Results from Ongoing Trials; Share Price Skyrockets ~37%

  • September 18, 2020 08:57 PM AEST
  • Team Kalkine
Immutep Highlights Improvement in Interim Results from Ongoing Trials; Share Price Skyrockets ~37%

Summary

  • Biotech player Immutep Limited reported interim data from its ongoing INSIGHT-004 Phase 1 clinical trial and Phase 2 TACTI-002 study.
  • The interim findings from INSIGHT-004 trial demonstrate that the combination of eftilagimod alpha with avelumab is well-tolerated and safe.
  • Combination of eftilagimod alpha and KEYTRUDA® was found to be safe and well-tolerated without any new safety signals.
  • Post these announcements share price of IMM rose by 37.209% to close the market at A$0.295 on 18 September 2020.

At the end of today’s trading session, the share price of ASX-listed biotech Company Immutep Limited (ASX:IMM) soared by 37.209% to close at A$0.295. With a market capitalisation of nearly A$104.84 million, Immutep has almost 487.63 million shares trading on the ASX.

The sharp rise in the share price was noted after the Company disclosed improving results in two clinical trials - INSIGHT-004 trial and TACTI-002 trial. The favourable update was well-received by the market participants. While the S&P/ASX 200 Health Care Sector index witnessed a drop of 0.99%, IMM share price surged in the opposite direction.

Let us delve deep and discuss in detail what Immutep has announced today-

About Immutep Limited

ASX-listed global biotechnology company, Immutep Limited is a frontrunner in developing LAG-3 related immunotherapeutic products for cancer & autoimmune disease treatment. The current lead product candidate of the Company is eftilagimod alpha which is a soluble LAG-3 protein. Eftilagimod is under clinical development for the treatment of different forms of cancers.

Improving Interim Results from INSIGHT-004 Trial

Immutep, today, reported additional interim data from its ongoing INSIGHT-004 Phase 1 clinical trial.

The Company stated that the data were presented at the ESMO Virtual Congress 2020 on 17 September 2020 by the trial investigator at Institute of Clinical Cancer Research.

INSIGHT-004 trial is assessing the combination of lead product candidate of Immutep, eftilagimod alpha with avelumab (BAVENCIO®), a human anti-PD-L1 antibody. The trial is being conducted under Immutep’s collaboration with Merck KGaA, and Pfizer Inc in 12 patients with various solid tumours, mainly gastrointestinal.

Summary of Clinical Trial Results

The Company disclosed that nearly 41.7% of patients (5 out of 12) demonstrated a partial response to the combination therapy, according to RECIST 1.1.

Source: IMM ASX Announcements

The interim findings from INSIGHT-004 trial demonstrate that the combination of eftilagimod alpha with avelumab is well-tolerated. The combination did not show any dose-limiting toxicities and hence building a strong safety profile of eftilagimod so far.

The Company stated that the promising initial anti-tumour activity signals in several cancer indications were not typically sensitive to ICI (immune checkpoint inhibitor) therapy.

Immutep Announces Interim data from its ongoing Phase 2 TACTI-002 study

The Company also disclosed new interim data from its ongoing TACTI-002 Phase 2 clinical trial. The Company stated that on 17 September 2020, the data was presented at the ESMO Virtual Congress 2020.

TACTI-002 trial is being conducted in partnership with Merck & Co Inc. The trial is assessing the combination of eftilagimod alpha with Merck’s KEYTRUDA® (pembrolizumab). The trial is underway in up to 109 patients having second-line head and neck squamous cell cancer (HNSCC, Part C) or non-small cell lung cancer in the first and second-line (Parts A & B, respectively).

In TACTI-002 clinical trial, patients are participating in three parts:

  • Part A – PD-X naive, first-line Non-Small Cell Lung Cancer (NSCLC).
  • Part B - PD-X refractory, second-line NSCLC.
  • Part C - PD-X naive, second-line Head and Neck Squamous Cell Carcinoma (HNSCC).

Clinical Trial Results Summary

Immutep stated that the combination therapy continues to be well-tolerated and safe without any new safety indications reported so far. Three complete responses with complete disappearance of all lesions were reported. Out of these, two were in second-line HNSCC, and one was in the first-line NSCLC.

Source: IMM ASX Announcements

Recruitment Update for TACTI-002 Trial

TACTI-002 clinical trial recruitment is progressing well with 89 patients out of up to 109 already enrolled at 12 clinical sites across the UK, US, Australia, and Europe.

The Company stated that at present, recruitment is going on for Stage 2 of Part C. Immutep shall consider opening Stage 2 of Part B for recruitment which is currently pending the recommendation of the Data Monitoring Committee (DMC).

Immutep anticipates reporting its first data from Stage 2 and more mature data from Stage 1 at a conference later this calendar year.

Bottomline

The interim data published by Immutep for two parallel clinical trials of eftilagimod alpha in different combinations showed positive outcomes and demonstrated both combinations are safe and well-tolerated. With the positive interim outcomes, the Company is confident to move ahead in the clinical trials.

ALSO READ: ASX-listed Cancer Stocks Under the Microscope- IMM, RAC, IVX, KZA

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK